# Diffuse Fibrotic Lung Disease

> **NCT00000596** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Lung Diseases
- Pulmonary Fibrosis
- Sarcoidosis

## Interventions

- **DRUG:** prednisone
- **DRUG:** cyclophosphamide
- **DRUG:** dapsone

## Key facts

- **NCT ID:** NCT00000596
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1978-06
- **Primary completion:** —
- **Final completion:** 1983-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000596, "Diffuse Fibrotic Lung Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00000596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*